Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | AKT2 | P31751 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3629993 | 1.00 | KCNN4 (0.55) | KCNN4TAAR1AKT1AKT2MAPK1 | |
| SCHEMBL6145 | 0.97 | KCNN4 (0.58) | KCNN4TAAR1AKT1AKT2MAPK1 | |
| Ammonia Solution, Strong SCHEMBL28009204 | 0.94 | KCNN4 (0.55) | KCNN4TAAR1AKT1AKT2MAPK1 | |
| Fluoride SCHEMBL634655 | 0.94 | KCNN4 (0.55) | KCNN4TAAR1AKT1AKT2MAPK1 | |
| Hydrochloric Acid SCHEMBL111457 | 0.94 | KCNN4 (0.55) | KCNN4TAAR1AKT1AKT2MAPK1 | |
| Hydrochloric Acid SCHEMBL8387827 | 0.94 | KCNN4 (0.55) | KCNN4TAAR1AKT1AKT2MAPK1 | |
| Iodide SCHEMBL6672017 | 0.94 | KCNN4 (0.55) | KCNN4TAAR1AKT1AKT2MAPK1 | |
| Water SCHEMBL4609376 | 0.94 | KCNN4 (0.55) | KCNN4TAAR1AKT1AKT2MAPK1 | |
| Methylamine SCHEMBL20916863 | 0.94 | KCNN4 (0.55) | KCNN4TAAR1AKT1AKT2MAPK1 | |
| Hydrochloric Acid SCHEMBL8388827 | 0.92 | KCNN4 (0.52) | KCNN4TAAR1AKT1AKT2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575357-B2 | Substituted (thiazolyl-carbonyl)imidazolidinones and use thereof | AICURIS GMBH & CO. KG (DE) | 2013-11-05 | — | — | US | disclosed |
| US-8546438-B2 | Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20130045999-A1 | SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2013-02-21 | — | — | US | disclosed |
| US-8324268-B2 | Substituted furancarboxamides, and use thereof | AICURIS GMBH & CO. KG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-8030347-B2 | Cylopenta[b]benzofuran derivatives and the utilization thereof | BAYER HEALTHCARE AG (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | BAYER HEALTHCARE AG (DE) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045999-A1 | SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF | TPMT, AADAC, PAICS | SLC6A2 4501/4885KCNN4 4183/4885TAAR1 3677/4885 |
| US-20120022059-A1 | SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF | AADAC, DDC, TPMT | SLC6A2 3317/4885KCNN4 3091/4885TAAR1 3548/4885 |
| US-20090018113-A1 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof | FKBP1A, FKBP2, FKBP1B | SLC6A2 4783/4885KCNN4 4598/4885TAAR1 4724/4885 |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | TPMT, MAVS, EIF2AK2 | SLC6A2 3719/4885KCNN4 4821/4885TAAR1 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.